Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02374060) enrolled 192 people across three groups to compare three different corticosteroid treatments for macular oedema — a condition where the central part of the retina swells with fluid. The three groups were: a steroid injection around the outside of the eye (periocular triamcinolone 40mg, 65 participants), a steroid injection directly into the eye (intravitreal triamcinolone 4mg, 63 participants), and a slow-release steroid implant placed inside the eye (dexamethasone intravitreal implant, 64 participants). The main thing being measured was how much the thickness of the central retina changed over 8 weeks, compared to where each participant started. The reported data shows that at 8 weeks, retinal thickness as a proportion of each participant's starting thickness was 0.77 for the periocular injection group, 0.61 for the intravitreal injection group, and 0.54 for the implant group — where a lower number means greater reduction in thickness from baseline. For the secondary outcomes at 8 weeks, the proportion of eyes that achieved at least a 20% reduction in retinal thickness (or returned to a normal thickness) was reported as 0.41 for periocular, 0.79 for intravitreal injection, and 0.84 for the implant group. The proportion of eyes where retinal thickness returned fully to a normal level at 8 weeks was reported as 0.20, 0.47, and 0.61 respectively. The reported data also shows results at 24 weeks. Retinal thickness as a proportion of baseline was 0.68 (periocular), 0.64 (intravitreal injection), and 0.61 (implant). The proportion of eyes with at least a 20% thickness reduction at 24 weeks was 0.61, 0.73, and 0.74, while the proportion with full return to normal thickness at 24 weeks was 0.35, 0.36, and 0.41 across the three groups respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 30269924) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have uveitis (inflammation inside the eye) that is not caused by an infection — it can be currently active or not active
- You have swelling in the central part of the retina (the back of the eye), as measured by a special eye scan called OCT
- Your vision in the affected eye is at least 5/200 (some usable vision, even if limited)
- Your eye pressure is within a specific range (between 5 and 21 mmHg), and you may still qualify if you use up to 3 eye pressure-lowering medications or have had glaucoma surgery
- You are able to have a dye-based eye scan (fluorescein angiogram) that clearly shows the central part of your retina
- Your pupil can be dilated enough to allow the OCT eye scan to be performed
Who may not be able to join:
- You have had an eye infection inside the eye, or conditions such as infectious uveitis, scleritis, keratitis, or infectious endophthalmitis in either eye
- You have a history of a condition called central serous retinopathy in either eye
- You are pregnant, breastfeeding, have a positive pregnancy test, or are not willing to use an adequate form of birth control for the duration of the trial (if you are a woman who could become pregnant)
- You are currently taking a specific type of fluid-reducing tablet called acetazolamide or a similar medication by mouth
- You are taking oral steroids (like prednisone) at a dose higher than 10 mg per day, or at any dose that has not been stable for at least the past 4 weeks
- You are taking immune-suppressing medications that have not been at a stable dose for at least the past 4 weeks
- You have a known allergy or sensitivity to any ingredient in the study medications
- You have severe glaucoma with significant damage to the optic nerve in the eye being studied
- There is something blocking the view of the back of your eye that prevents the OCT scan from being done
- You have significant scar tissue on the surface of your retina (called an epiretinal membrane) that may prevent the swelling from improving, as judged by the study eye doctor
- The back part of the lens in your eye is torn or damaged
- You have silicone oil in your eye (sometimes used after retinal surgery)
- You have had a steroid injection in or around the affected eye in the past 8 weeks
- You have had a specific type of steroid eye implant (dexamethasone implant) in the past 12 weeks
- You have had a long-acting steroid implant called Retisert placed in your eye in the past 3 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Douglas A Jabs, MD, MBA, Icahn School of Medicine, Noutn Sinai, New York, NY
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.